Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis by Ciardi, Maria R et al.
I D  C A S E
ID CASE • OFID • 1
Open Forum Infectious Diseases
 
Received 11 November 2018; editorial decision 18 December 2018; accepted 21 December 
2018; published online December 26, 2018
Correspondence: Marco Iannetta, MD, PhD, Department of Public Health and Infectious 
Diseases, Sapienza, University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy (marco.ian-
netta@uniroma1.it).
Open Forum Infectious Diseases®
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the 
work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofy356
Reactivation of Hepatitis B Virus With 
Immune-Escape Mutations After 
Ocrelizumab Treatment for Multiple 
Sclerosis
Maria R. Ciardi,1,  Marco Iannetta,1,  Maria A. Zingaropoli,1,  Romina Salpini2,   
Marianna Aragri,2 Rosanna Annecca,3 Simona Pontecorvo,3,  Marta Altieri,3  
Gianluca Russo,1,  Valentina Svicher,2,  Claudio M. Mastroianni,1,  and Vincenzo 
Vullo1,
1Department of Public Health and Infectious Diseases, Sapienza, University of Rome, Rome, 
Italy; 2Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 
Rome, Italy; 3Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy
Ocrelizumab is an anti-CD20 monoclonal antibody for the 
treatment of multiple sclerosis (MS) that is closely related to 
rituximab. We describe a case of hepatitis B virus (HBV) reacti-
vation in an MS patient with resolved HBV infection receiving 
ocrelizumab. HBV reactivation was monitored with HBV-DNA 
and HBV surface antigen periodic assessment. Anti-HBV treat-
ment with entecavir was started after HBV-DNA detection. 
Ocrelizumab can reactivate viral replication in patients with 
resolved HBV infection. HBV reactivation monitoring seems an 
effective and safe option for the management of these patients. 
More studies are needed to assess the optimal management of 
HBV reactivation in MS patients on ocrelizumab treatment.
Keywords.  HBV; CD20; liver; biologics; entecavir; 
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Ocrelizumab is an anti-CD20 monoclonal antibody for the 
treatment of primary progressive (PP) and relapsing (R) mul-
tiple sclerosis (MS) [1, 2]. Given the homology of ocrelizumab 
with other B-cell-targeting disease-modifying therapies (DMTs; 
such as rituximab), hepatitis B virus (HBV) reactivation is con-
sidered possible [1–3]. Current guidelines recommend either 
HBV prophylaxis or periodic monitoring for HBV surface 
antigen (HBsAg)–negative, anti-HBV core antigen antibody 
(HBcAb)–positive, HBV-DNA-negative subjects at high risk 
(>10%) or moderate to low risk (<10%) of HBV reactivation, 
respectively [4, 5]. Here we describe a case of HBV reactivation 
in an HBsAg-negative/HBcAb-positive patient on ocrelizumab 
treatment for MS.
CASE REPORT
A 60-year-old Caucasian man affected by primary progressive 
multiple sclerosis (PPMS) since 2012, with an expanded disabil-
ity status scale of 6.5 and previous treatment with azathioprine, 
was started on ocrelizumab in February 2018. Pre-ocrelizumab 
serologic tests showed the presence of antibodies to HBV sur-
face (10.02 mUI/mL; lower detection limit, 2.5 mUI/mL) and 
core antigens (HBsAb and HBcAb, respectively), whereas HBV 
surface and e antigens (HBsAg and HBeAg, respectively) and 
antibodies to HBV e antigen (HBeAb) were negative. HBV-
DNA was undetectable (<20 IU/mL), white blood cell (WBC) 
counts, lymphocyte percentages, and liver enzymes were within 
normal ranges. HBV reactivation was monitored, with monthly 
assessment of liver enzymes, HBsAg, and HBV-DNA. Six week 
after first ocrelizumab administration, HBV-DNA became 
detectable (41 IU/mL) and increased to 132 and 184 IU/mL 
at 10 and 13 weeks, respectively. The patient remained asymp-
tomatic, and liver enzymes and WBC counts were unchanged 
(Figure 1), HBsAg remained undetectable. HBV phylogenetic 
analysis revealed a viral genotype D (subgenotype D3). No 
known drug resistance mutations were found in the reverse 
transcriptase gene (RT). Conversely, preS/S gene (encoding for 
HBsAg) was characterized by the mutation S117N, introduc-
ing a new N-linked glycosylation site on HBsAg, and P120T, 
C124Y, and G145A were localized in the major hydrophilic 
HBsAg region and known to act as immune-escape mutations. 
Furthermore, a stop codon was found at position 223, causing 
the production of a defective HBsAg. Treatment for HBV reac-
tivation with entecavir 0.5 mg once daily was started, and HBV-
DNA rapidly decreased to 100 IU/mL after 2 days of treatment, 
and below 20 IU/mL (detectable under the lower limit of quan-
tification) at 2 and 4 weeks after first entecavir administration. 
Twenty-four weeks after ocrelizumab initiation, HBV-DNA 
was undetectable, and the patient received the scheduled dose 
of ocrelizumab. The patient remained asymptomatic, and liver 
enzymes and WBC counts were within normal ranges (Figure 
1). HBsAg was persistently undetectable. The patient is cur-
rently under follow-up.
DISCUSSION
Ocrelizumab can reactivate latent HBV infection in PPMS 
patients. In a previous report, ocrelizumab and methotrexate 
combined therapy was linked to HBV reactivation in a patient 
with rheumatoid arthritis [6]. Furthermore, rituximab-based 
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therapy for rheumatologic diseases has been associated with 
HBV reactivation in HBsAg-negative/HBcAb-positive subjects, 
with an increased risk for HBsAb-negative subjects [7].
In our case, the enrichment of immune-escape mutations 
in the preS/S gene encoding for HBsAg could have promoted 
the restoration of viral replication in the setting of suboptimal 
humoral immune response. The complex HBsAg mutational 
profile identified in this patient, together with the presence 
of a stop codon, which is associated with intracellular HBsAg 
retention, could have impaired HBsAg recognition by diagnos-
tic antibodies, thus explaining the undetectability of HBsAg 
[8–10].
Current guidelines suggest starting prophylaxis for HBV 
reactivation for those subjects initiating an immune-suppress-
ing treatment at high risk for HBV reactivation (>10%), and 
HBV reactivation monitoring can be adopted for patients at 
moderate (1%–10%) and low risk (<1%). Universal prophylaxis 
is generally recommended in selected clinical settings, such 
as long duration of immunosuppression, limited compliance 
to monitoring, or unknown risk of viral reactivation for new 
DMTs [4, 5]. HBV reactivation monitoring with HBV-DNA 
periodic assessment may not be cost-effective in special health 
care settings where low-cost entecavir is available.
Considering the absence of onco-hematological diseases, 
the experience derived from rituximab use in rheumatologic 
diseases [7, 11] and the positivity for HBsAb (despite a low 
titer) before ocrelizumab administration, in our patient HBV 
reactivation was managed with periodic monitoring instead of 
prophylaxis. HBV reactivation treatment with a potent antivi-
ral agent seems to be an effective and safe option for HBsAg-
negative/HBcAb-positive/HBV-DNA-negative patients starting 
ocrelizumab. HBV prophylaxis or reactivation monitoring can 
prevent ocrelizumab discontinuation. Moreover, compared 
with universal prophylaxis, periodic monitoring could spare 
HBV treatment in unnecessary cases. When starting prophy-
laxis or a therapy for HBV in the setting of immune-suppress-
ing treatments, a long-term course of anti-HBV therapy should 
be considered and a high–genetic barrier antiviral is advisable 
in order to reduce the risk of drug resistance strain emergence. 
For this reason, entecavir is preferred over lamivudine in our 
patients, whereas tenofovir was spared for use in case of further 
HBV reactivation during entecavir treatment [12, 13].
Of note, HBV treatment should be continued for at least 12 
months after B-lymphocyte-targeting drug discontinuation [13].
More studies are needed to define HBV reactivation risk 
during ocrelizumab treatment and the best approach for its 
management.
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Figure 1. Longitudinal evaluation of hepatitis B virus (HBV)–DNA, liver enzymes, and white blood cell counts before and after ocrelizumab treatment. A, HBV-DNA, alanine 
aminotransferase (ALT), and aspartate aminotransferase (AST) modifications over time during ocrelizumab treatment. B, White blood cell absolute counts and neutrophil, 
lymphocyte, and monocyte percentages over time during natalizumab treatment. Arrows represent ocrelizumab infusions. Horizontal dotted line: HBV-DNA lower limit 
of quantification (20 IU/mL). HBV-DNA was detected and quantified using the Cobas AmpliPrep/CobasTaqman HBV Test (Roche Molecular Diagnostic, Pleasanton, CA). 
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ETV, entecavir; Ocre, ocrelizumab; WBC, white blood cells.
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